1Hollander P. Acarbose ADRs predominantly GI Safety of acarbose, an al- pha- glucosidase inhibitor [J]. Drugs, 1992, 44 (Suppl 3): 47- 53.
2Lorenzi M, Montisano DF, Toledo S. High glucose induces DNA dam- age in cultured human endothelial cell [J]. J clin Invest, 1986, 77:. 322.
3Victor JN, John RS. Current concepts: Drug - related hepatotoxicity [J]. N Engl J Med, 2006, 354 (7) : 731 -739.
4Rojas LB, Gomes MB. Metformin, an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr , 2013, 5:6.
5Pablo Aschner Bogota, Henning Beck-Nielsen O, Peter B, et al. Global Guideline for Type 2 Diabetes. International Diabetes Federation, 2012.
6Bodmer M,Meier C,Kriihenbuhl Svet al. Metformin, Sulfonylureas , or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia. Diabetes Care, 2008, 31: 2086-2091.
7Salpeter S, Greyber E, Pasternak G, et al., Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev, 2010, 4: CD002967.
8Kajbaf F, Lalau JD. The criteria for metformin-associated lactic acidosis: the quality of reporting in a large pharmacovigilance database. Diabet Med, 2013, 30: 345-348.
9Avogaro A, Schernthaner G. Acta Diabetol Achieving glycemic control in patients with type 2 diabetes and renal impairment. Acta Diabetol, 2013, 50: 283-291.
10Scheen AJ, Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab, 2013, 39: 179-190.
